Gemcitabine-loaded microbubble system for ultrasound imaging and therapy

Delaney, Lauren J; Eisenbrey, John R.; Brown, David; Brody, Jonathan R.; Jimbo, Masaya; Oeffinger, Brian; Stanczak, Maria; Forsberg, Flemming; Liu, Ji‐Bin; Wheatley, Margaret A.

doi:10.1016/j.actbio.2021.05.046

Cited by 23 publications

(20 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Theranostic NPs have also been evaluated in several studies for targeting PDAC. Gemcitabine, which is the first-line therapy for PDAC, has been encapsulated in various NP formulations, including microbubbles (for ultrasound imaging) 191 , luminescent photothermal NPs 192 , and PLGA nanospheres containing fluorescent iron oxide NPs 193 . Urokinase plasminogen activator receptor (uPAR)-targeted, PEGylated iron oxide NPs labeled with NIR dye (NIR 830-maleimide) and loaded with doxorubicin (DOX) or cisplatin were also evaluated in a syngeneic orthotopic model of PDAC.…”

Section: Nanocarrier-based Delivery Of Therapeutic Imaging and Theran...mentioning

confidence: 99%

Nanocarriers for pancreatic cancer imaging, treatments, and immunotherapies

Liu¹,

Kshirsagar²,

Gautam³

et al. 2022

Theranostics

View full text Add to dashboard Cite

Pancreatic tumors are highly desmoplastic and immunosuppressive. Delivery and distribution of drugs within pancreatic tumors are compromised due to intrinsic physical and biochemical stresses that lead to increased interstitial fluid pressure, vascular compression, and hypoxia. Immunotherapy-based approaches, including therapeutic vaccines, immune checkpoint inhibition, CAR-T cell therapy, and adoptive T cell therapies, are challenged by an immunosuppressive tumor microenvironment. Together, extensive fibrosis and immunosuppression present major challenges to developing treatments for pancreatic cancer. In this context, nanoparticles have been extensively studied as delivery platforms and adjuvants for cancer and other disease therapies. Recent advances in nanotechnology have led to the development of multiple nanocarrier-based formulations that not only improve drug delivery but also enhance immunotherapy-based approaches for pancreatic cancer. This review discusses and critically analyzes the novel nanoscale strategies that have been used for drug delivery and immunomodulation to improve treatment efficacy, including newly emerging immunotherapy-based approaches. This review also presents important perspectives on future research directions that will guide the rational design of novel and robust nanoscale platforms to treat pancreatic tumors, particularly with respect to targeted therapies and immunotherapies. These insights will inform the next generation of clinical treatments to help patients manage this debilitating disease and enhance survival rates.

show abstract

Section: Nanocarrier-based Delivery Of Therapeutic Imaging and Theran...mentioning

confidence: 99%

Nanocarriers for pancreatic cancer imaging, treatments, and immunotherapies

Liu¹,

Kshirsagar²,

Gautam³

et al. 2022

Theranostics

View full text Add to dashboard Cite

show abstract

“…However, due to the confined volume available for drug loading, the amount of drug that can be incorporated into a microbubble shell or membrane is limited. 60,61 In addition, attaching or incorporating a drug into the UCA microbubble shell may alter the biological activity of the drug or the acoustic capabilities of the UCA. [61][62][63] Lipid-based microbubbles and UCA currently dominate the UTDD literature, due to their ease of fabrication, flexibility and versatility, immediate release profile, and commercial availability.…”

Section: Materials Advances Reviewmentioning

confidence: 99%

“…60,61 In addition, attaching or incorporating a drug into the UCA microbubble shell may alter the biological activity of the drug or the acoustic capabilities of the UCA. [61][62][63] Lipid-based microbubbles and UCA currently dominate the UTDD literature, due to their ease of fabrication, flexibility and versatility, immediate release profile, and commercial availability. [64][65][66] Briefly, these agents are comprised of a monolayer of lipids surrounding a gas core, where both the lipid and the gas can be selected to influence the behavior and loading of the agent.…”

Section: Materials Advances Reviewmentioning

confidence: 99%

“…63,82 Recently, this group also showed some success in encapsulating gemcitabine within a PLA microbubble for treatment against MiaPaCa-2 pancreatic cancer cells. 61 However, the in vitro success did not translate into tumor suppression in a mouse model (Fig. 3), highlighting the limitations of drug loading capacity within microbubbles.…”

Section: Materials Advances Reviewmentioning

confidence: 99%

“…3), highlighting the limitations of drug loading capacity within microbubbles. 61 In an effort to improve drug loading and delivery, Teraphongphom et al demonstrated the feasibility of loading quantum dots, magnetic iron oxide nanoparticles, and gold nanoparticles within the shell of PLA microbubbles, suggesting that these modalities could provide opportunities for multimodal imaging techniques or therapeutics. 83 Microbubbles can also be used to carry other factors, such as genes or gases, that can be used to improve cancer treatments.…”

Section: Materials Advances Reviewmentioning

confidence: 99%

See 2 more Smart Citations